Guggenheim Cuts Illumina (NASDAQ:ILMN) Price Target to $150.00

Illumina (NASDAQ:ILMN) had its target price decreased by Guggenheim from $170.00 to $150.00 in a research note released on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the life sciences company’s stock.

Other equities analysts also recently issued reports about the stock. Barclays reduced their target price on shares of Illumina from $145.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Monday, February 3rd. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. Robert W. Baird boosted their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Finally, Stephens boosted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Nine equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.40.

Illumina Stock Performance

NASDAQ:ILMN opened at $111.06 on Friday. The company’s 50-day moving average price is $136.70 and its 200-day moving average price is $135.43. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The company has a market cap of $17.61 billion, a P/E ratio of -14.46 and a beta of 1.10. Illumina has a twelve month low of $100.08 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, sell-side analysts forecast that Illumina will post 4.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers boosted its holdings in shares of Illumina by 25.8% in the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after buying an additional 3,767 shares in the last quarter. Diversified Trust Co acquired a new position in shares of Illumina in the 3rd quarter valued at $243,000. CWM LLC boosted its holdings in shares of Illumina by 179.8% in the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock valued at $2,114,000 after buying an additional 10,414 shares in the last quarter. Perpetual Ltd acquired a new position in shares of Illumina in the 3rd quarter valued at $723,000. Finally, UMB Bank n.a. boosted its holdings in shares of Illumina by 23.7% in the 3rd quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock valued at $216,000 after buying an additional 318 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.